# U-Synbio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/u-synbio

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.usynbio.com
- Latest round: Angel (Feb 23, 2022)
- Investors on record: 3

## About

Based in Suzhou, China, and established in 2021, U-Synbio is a biotechnology company that focuses on the fields of synthetic biology. The company's founder is Dr.Jingyu Chen, who graduated from Tsinghua University and serves as an associate professor at China Agricultural University. The company's CTO is Guoqiang Chen, who serves as a Changjiang Scholar, and a 973 Synthetic Biology Expert.

The company is establishing a Live biotherapeutic products (LBP) platform, based on synthetic biology technology. The LBP contains live organisms, such as bacteria, and is not a vaccine. The LBP's drug delivery method adopts oral. The LBP is applicable to the prevention, and treatment of tumors.

The company will use the angel funding to establish an R&D center, to R&D new products, and to upgrade the technology platform.

## Funding rounds

- Angel, Feb 23, 2022 — Innoangel Fund, Beijing Zhenghegu Technology Development, Leader Venture Capital

## Investors

- Innoangel Fund (https://capitalatlas.ai/funds/innoangel-fund) — Angel
- Beijing Zhenghegu Technology Development — Angel
- Leader Venture Capital (https://capitalatlas.ai/funds/leader-venture-capital) — Angel